Sarcopenia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Sarcopenia is a musculoskeletal condition characterized by a progressive decrease in muscle mass and strength, especially in older people. Reduced levels of muscle strength, muscle quantity or quality, and physical performance are all included in the diagnosis of Sarcopenia. Such musculoskeletal deterioration has predictive value for adverse postoperative outcomes, higher rates of complications, death, and morbidity following major surgical procedures, and the inability to carry out daily tasks. Sarcopenia usually results from normal aging processes, which have many different and poorly understood causes. Reduced size and quantity of type II muscular fibers, inactivity, obesity, insulin resistance, lower serum concentrations of androgen and growth factors, insufficient protein consumption, and a blunted response of Muscle Protein Synthesis (MPS) to protein are some of the factors that lead to its development. Age-related decreases in serum concentrations of anabolic hormones: Anabolic hormones, including testosterone, human growth hormone (HGH), and Insulin-Like Growth Factor-1 (IGF-1), have a role in the formation, preservation, or regeneration of muscle tissue at normal physiological serum levels. Patients with Sarcopenia have age-related decreases in these hormones, which lends support to the underlying pathophysiology of the condition. Handgrip strength is one of the two techniques typically used to measure muscle strength in patients with suspected Sarcopenia. Consuming protein is a crucial component of nutritional therapy for Sarcopenia. According to the European Working Group on Sarcopenia in Older People (EWGSOP2), treatment plans should include healthy protein intake and exercise recommendations. Currently, there is no FDA-approved product for the treatment of sarcosis. For Sarcopenia, the combination of exercise therapy and nutrition may be more beneficial than either treatment alone.

Thelansis’s “Sarcopenia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sarcopenia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Sarcopenia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Sarcopenia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Sarcopenia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033